GLP-1 and Sleep Apnea: The SURMOUNT-OSA Trial Evidence

Obstructive sleep apnea (OSA) and obesity are tightly linked — excess weight around the neck and airway is a major driver of the condition — so it's not surprising a weight-loss drug would help. What's notable is how much it helped, and that the effect was large enough to become tirzepatide's second FDA-approved indication under the Zepbound brand. Here's the trial behind that approval.

The trial design

SURMOUNT-OSA randomized adults with obesity and moderate-to-severe obstructive sleep apnea into two parallel trials: one enrolling participants who weren't using positive airway pressure (PAP) therapy, the other enrolling participants who were already on PAP and continued it throughout¹. Both trials measured the apnea-hypopnea index (AHI) — the number of breathing interruptions per hour of sleep, the standard clinical measure of OSA severity — comparing tirzepatide against placebo.

The results

In the PAP-naive trial, tirzepatide reduced AHI by 25.3 events per hour on average, versus 5.3 events per hour on placebo — a treatment difference of 20.0 events per hour (P<0.001)¹. In the PAP-treated trial, the gap was similar: tirzepatide reduced AHI by 29.3 events per hour versus 5.5 on placebo, a treatment difference of 23.8 events per hour (P<0.001)¹. For context, a drop of 20+ events per hour is frequently enough to move a patient down an entire OSA severity category — from severe to mild, or in some cases below the diagnostic threshold altogether — though the trial reported the AHI change itself rather than reclassifying every participant's severity category. Both trials also reported "significant improvements... for all prespecified key secondary end points," including body weight, hypoxic burden (how much and how deeply oxygen levels drop during apnea events), a key inflammatory marker (hs-CRP), systolic blood pressure, and patient-reported sleep quality¹. The adverse-event profile was consistent with tirzepatide's established side-effect pattern: "gastrointestinal in nature and mostly mild to moderate in severity"¹ — the same GI symptoms covered in GLP-1 side effects: what the STEP and SURMOUNT trials actually reported.

Why this became an approved indication, not just a talking point

A large, well-designed randomized trial with a hard clinical endpoint (AHI, not a subjective symptom score) is exactly what the FDA requires to add a new approved use to a drug's label — and it worked: Zepbound's current label lists moderate-to-severe obstructive sleep apnea in adults with obesity as an approved indication². That's a meaningfully different regulatory bar than an off-label anecdote or a smaller pilot study. It also means insurance coverage for Zepbound specifically for OSA is now a real possibility for patients with that diagnosis, separate from the weight-management indication — worth raising directly with your prescriber and insurer if OSA is part of your picture, since coverage rules for the same drug can differ by indication, a pattern we cover more broadly in Mounjaro vs Zepbound: same drug, different price.

What this doesn't mean

This is Zepbound (tirzepatide)-specific trial evidence tied to a specific FDA approval — it doesn't automatically transfer to semaglutide (Wegovy/Ozempic) claiming the same OSA benefit, since semaglutide hasn't run the equivalent trial or received the equivalent label indication as of this writing. If OSA is a major factor in your drug choice, that's worth confirming directly rather than assuming every GLP-1 carries the same approval. See Wegovy vs Zepbound: what's actually different for the fuller picture of how the two brands' approved uses have diverged.

It's not a replacement for PAP therapy on its own

Notably, one of the two SURMOUNT-OSA trials specifically studied tirzepatide added on top of continued PAP use, not as a PAP replacement — the trial design itself treats the drug as an adjunct for many patients, not an automatic substitute for standard OSA treatment. Whether you can safely reduce or stop PAP therapy after starting tirzepatide is a decision for a sleep-medicine clinician working from your own follow-up testing, not something this trial data settles on its own.

Where this fits your provider decision

If sleep apnea is part of why you're considering a GLP-1, ask a prospective program whether their intake even asks about it — a program focused purely on weight-loss marketing may not connect OSA to your treatment plan at all. We score real medical oversight as part of our Value Score methodology; compare pricing on our tirzepatide price board, and check intake depth in our provider reviews.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.